Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Clinical trial NCT04610866 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04610866
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-09
- Primary completion
- 2028-02-28
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.